drug affinity complex is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-30. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
=== Alloys === A widely used zinc alloy is brass, in which copper is alloyed with anywhere from 3% to 45% zinc, depending upon the type of brass. Brass is generally more ductile and stronger than copper, and has superior corrosion resistance. These properties make it useful in communication equipment, hardware, musical instruments, and water valves.
=== Opposition to use of face masks by employees (2023) === In July 2023, the company announced that employees in Nevada, Arizona, Utah, Texas and Colorado would not be allowed to wear protective face masks at work, unless they could prove a valid medical exemption. The stated reason was to "emphasize the importance of customer service and the ability to show our associates' smiles and other facial features", according to a company memo. The company's communications department sent a statement from chief operating officer Denny Warnick to SFGATE: "We believe that wearing a mask literally adds a barrier to communication — much of which is nonverbal — and promotes a more distant and disconnected environment."
== SM == sm – (s) Samoan language (ISO 639-1 code) Sm – (s) Samarium SM (i) Sado-Masochism (s) San Marino (ISO 3166 and FIPS 10-4 country code digram) (i) Soldier's Manual (s) Submarine Minelayer (US Navy hull classification) SMA – (i) Scan Mirror Assembly SMART - many different meanings SMASS – (a) Small Main-Belt Asteroid Spectroscopic Survey SMB – (i) Super Mario Bros. SMCT – (i) Soldier's Manual of Common Tasks SMD – (i) Surface Mount Device SMDR – (i) Station Message Detail Recording sme – (s) Northern Sami language (ISO 639-2 code) SME (i) Scan Mirror Electronics Subject Matter Expert SMG (i) Sequential Motorsport Gearbox SubMachine Gun SMH – (a) Shaking My Head SMil – (a) Sadomasochisterne i landet (Danish SM organisation) SMIL – (a) Synchronized Multimedia Integration Language smo – (s) Samoan language (ISO 639-2 code) SMP – (i) Standard Military Pattern SM&R – (i) Source, Maintenance, and Recoverability SMR – (s) San Marino (ISO 3166 trigram) SMS – many, including: Short message service; see entry SMTP – (i) Simple Mail Transfer Protocol SMU – (i) Southern Methodist University SMV – (i) Symbolic model verification SMX many, including: (i) Server Macro Expansion (p) Solaris MINIX (p) Spatial multiplexing (p) Sulfamethoxazole; see entry SMZ many, including: (i) Silver Mt. Zion (p) Sulfamethazine (p) Sulfamethoxazole; see entry
Sources: en.wikipedia.org
In the most common means for its production, cells make 5-oxo-ETE in a four step pathway that involves their stimulus-induced activation of the following pathway: a) the release of arachidonic acid (i.e. 5Z,8Z,11Z,14Z-eicosatetraenoic acid) from its storage sites in membrane phospholipids due to the activation of phospholipase A2 enzymes; b) oxygenation of this arachidonic acid by activated arachidonate 5-lipoxygenase (ALOX5) to form 5(S)-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(S)-HpETE); c) reduction of this 5(S)-HpETE by ubiquitous cellular peroxidases to form 5(S)-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(S)-HETE); and (d) the oxidation of 5(S)-HETE by a microsome-bound nicotinamide adenine dinucleotide phosphate (NADP+)-dependent dehydrogenase enzyme viz., 5-hydroxyeicosanoid dehydrogenase (5-HEDH), to form 5-oxo-ETE:
year is the laboratory's determination of the age of the sample, in radiocarbon years range is the laboratory's estimate of the error in the age, at 1σ confidence. 'BP' stands for "before present", referring to a reference date of 1950, so that "500 BP" means the year AD 1450. For example, the uncalibrated date "UtC-2020: 3510 ± 60 BP" indicates that the sample was tested by the Utrecht van der Graaff Laboratorium ("UtC"), where it has a sample number of "2020", and that the uncalibrated age is 3510 years before present, ± 60 years. Related forms are sometimes used: for example, "2.3 ka BP" means 2,300 radiocarbon years before present (i.e. 350 BC), and "14C yr BP" might be used to distinguish the uncalibrated date from a date derived from another dating method such as thermoluminescence. Calibrated 14C dates are frequently reported as "cal BP", "cal BC", or "cal AD", again with 'BP' referring to the year 1950 as the zero date. Radiocarbon gives two options for reporting calibrated dates. A common format is "cal date-range confidence", where:
=== Damaging and overloading === If a lithium-ion battery is damaged, crushed, or subjected to a higher electrical load without having overcharge protection, problems may arise. External short circuit can trigger a battery explosion. Such incidents can occur when lithium-ion batteries are not disposed of through the appropriate channels, but are thrown away with other waste. The way they are treated by recycling companies can damage them and cause fires, which in turn can lead to large-scale conflagrations. Twelve such fires were recorded in Swiss recycling facilities in 2023. If overheated or overcharged, Li-ion batteries may suffer thermal runaway and cell rupture. During thermal runaway, internal degradation and oxidization processes can keep cell temperatures above 500 °C, with the possibility of igniting secondary combustibles, as well as leading to leakage, explosion or fire in extreme cases. To reduce these risks, many lithium-ion cells (and battery packs) contain fail-safe circuitry that disconnects the battery when its voltage is outside the safe range of 3–4.2 V per cell, or when overcharged or discharged. Lithium battery packs, whether constructed by a vendor or the end-user, without effective battery management circuits are susceptible to these issues. Poorly designed or implemented battery management circuits also may cause problems; it is difficult to be certain that any particular battery management circuitry is properly implemented.
The decisive victory of Lieutenant-General Bernard Montgomery's Eighth Army over the Germans and Italians at the Second Battle of El Alamein in October–November 1942 turned the tide of the North African war strongly in favour of the Allies, and did much to revive Allied morale. The Rhodesians of the KRRC took part in the battle as part of the 7th Armoured Division under the XIII Corps, forming part of the initial thrust in the southern sector. The Rhodesian Anti-Tank Battery under Major Guy Savory also fought at El Alamein, supporting the Australian 9th Division as part of the XXX Corps. The fighting around "Thompson's Post" between 1 and 3 November was some of the fiercest Rhodesians took part in during the war. Hoping to knock out the Allied anti-tank guns before counter-attacking, the Germans concentrated intense artillery fire on the Australian and Rhodesian guns before advancing 12 Panzer IV tanks towards the weakest point of the Australian line. The Australian six-pounders had been largely disabled by the bombardment but most of the Rhodesian guns remained operational. The Rhodesian gunners disabled two Panzers and seriously damaged two more, compelling an Axis retreat, and held their position until being relieved on 3 November. One Rhodesian officer and seven other ranks were killed and more than double that number were wounded. For his actions at Thompson's Post, Sergeant J A Hotchin received the Distinguished Conduct Medal; Lieutenants R J Bawden and H R C Callon won the Military Cross and Trooper P Vorster the Military Medal.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.